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Abstract 
Background: Avermectin and milbemycin are important 16‑membered macrolides that have been widely used 
as pesticides in agriculture. However, the wide use of these pesticides inevitably causes serious drug resistance, it is 
therefore imperative to develop new avermectin and milbemycin analogs. The biosynthetic gene clusters of aver‑
mectin and milbemycin have been identified and the biosynthetic pathways have been elucidated. Combinatorial 
biosynthesis by domain swap provides an efficient strategy to generate chemical diversity according to the module 
polyketide synthase (PKS) assembly line.
Results: The substitution of aveDH2‑KR2 located in avermectin biosynthetic gene cluster in the industrial avermec‑
tin‑producing strain Streptomyces avermitilis NA‑108 with the DNA regions milDH2‑ER2‑KR2 located in milbemycin 
biosynthetic gene cluster in Streptomyces bingchenggensis led to S. avermitilis AVE‑T27, which produced ivermectin B1a 
with high yield of 3450 ± 65 μg/ml. The subsequent replacement of aveLAT‑ACP encoding the loading module of 
avermectin PKS with milLAT‑ACP encoding the loading module of milbemycin PKS led to strain S. avermitilis AVE‑H39, 
which produced two new avermectin derivatives 25‑ethyl and 25‑methyl ivermectin (1 and 2) with yields of 951 ± 46 
and 2093 ± 61 μg/ml, respectively. Compared to commercial insecticide ivermectin, the mixture of 25‑methyl and 
25‑ethyl ivermectin (2:1 = 3:7) exhibited 4.6‑fold increase in insecticidal activity against Caenorhabditis elegans. 
Moreover, the insecticidal activity of the mixture of 25‑methyl and 25‑ethyl ivermectin was 2.5‑fold and 5.7‑fold higher 
than that of milbemycin A3/A4 against C. elegans and the second‑instar larva of Mythimna separate, respectively.
Conclusions: Two new avermectin derivatives 25‑methyl and 25‑ethyl ivermectin were generated by the domain 
swap of avermectin PKS. The enhanced insecticidal activity of 25‑methyl and 25‑ethyl ivermectin implied the poten‑
tial use as insecticide in agriculture. Furthermore, the high yield and genetic stability of the engineered strains S. aver-
mitilis AVE‑T27 and AVE‑H39 suggested the enormous potential in industrial production of the commercial insecticide 
ivermectin and 25‑methyl/25‑ethyl ivermectins, respectively.
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Background
Avermectins and milbemycins (Fig.  1), the 16-mem-
bered macrolide antibiotics with potent anthelmintic and 
insecticidal activity, have been widely used for broad-
spectrum parasite control in agricultural, medical, and 
veterinary fields [1–3]. They are structurally related com-
pounds with structural differences at C25, C22–C23, and 
C13, leading to their own unique ‘spectral fingerprint’ 
with various strengths and dosage-limiting species. The 
subsequent chemically modification of avermectins 
and milbemycins resulted in series of analogs, some of 
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which are commercially developed as anthelmintics and 
insecticides, such as ivermectin, selamectin, abamectin, 
emamectin, doramectin, milbemycin oxime, lepimec-
tin, and latidectin [2]. Among these analogs, ivermectin 
(22,23-dihydroavermectin B1), showing the same effec-
tive antiparasitic activity and lesser toxic side effect than 
avermectins B1, has been worldwide used as an anthel-
mintic for livestock and companion animals and as an 
agricultural insecticide. Moreover, ivermectin has also 
been applied in human medicine, particularly treatment 
of onchocerciasis and lymphatic filariasis [4]. In the case 
of milbemycins, moxidectin is currently undergoing a 
phase III clinical trial to compare its efficacy with iver-
mectin in subjects with Onchocerca volvulus infection 
[1]; milbemycin oxime has been used against intestinal 
nematodes in dogs and cats, against adult heartworm 
in dogs, and against ectoparasites in companion ani-
mals [5]. Recently, it has been reported that ivermectin, 
selamectin and moxidectin demonstrated antibacterial 
activity against Mycobacterium tuberculosis, especially 
the multidrug-resistant and extensively drug-resistant 
clinical strains [1]. The approval for clinical and veteri-
nary uses as well as the documented pharmacokinetic 
and safety profiles of these compounds make them 
potential therapeutic options for treating M. tuberculo-
sis. The outstanding activities of avermectins and milbe-
mycins together with the potential uses in the filed of 
human medicine and agriculture stimulate the semisyn-
thetic derivatives of avermectins and milbemycins. On 
the other hand, the wide use of avermectins in agricul-
ture has inevitably caused serious drug resistance [2], it is 
therefore imperative to develop novel avermectins.
The previously established industrial process for pre-
paring the analogs of avermectins and milbemycins 
involves extracting avermectins or milbemycins from 
the fermentation broth and the subsequently chemi-
cal modification. However, this process suffers several 
drawbacks, such as the expensive cost, the heavy metal 
pollution, and low efficiency [3, 6–8]. Fortunately, the 
combinatorial biosynthesis and genetic manipulation 
provide alternative and efficient strategies to gener-
ate the known semi-biosynthetic polyketides and new 
hybrid compounds according to the module polyketide 
synthase (PKS) assembly line [3, 9, 10]. For example, on 
the basis of understanding the biosynthetic mechanism 
of avermectin, 22,23-dihydroavermectins including iver-
mectin were successfully produced by direct fermen-
tation of engineered S. avermitilis, in which the DNA 
Fig. 1 The structures of avermectins, milbemycins, and 25‑methyl/25‑ethyl ivermectin (1 and 2)
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region encoding the dehydratase (DH) and ketoreductase 
(KR) domains of module 2 from the avermectin PKS was 
replaced by the DNA fragment encoding the DH, enoyl-
reductase (ER), and KR domains of module 13 from the 
rapamycin PKS, module 4 from the pikromycin PKS, or 
module 3 from the oligomycin PKS [6, 8, 11]. Tradition-
ally, doramectin is produced by a bkd mutant S. aver-
mitilis, which blocks the formation of the starter units 
(isobutyryl-CoA and 2-methylbutyryl-CoA) of avermec-
tin biosynthesis, with the addition of cyclohexanecar-
boxylic acid (CHC) to the fermentation broth. While, it 
can be successfully produced without CHC supplemen-
tation if the CHC-CoA biosynthetic gene cassette was 
introduced into the bkd mutant S. avermitilis [12]. Fur-
thermore, it has been reported that the replacement of 
the loading module of avermectin PKS by a cyclohexane-
carboxylic unique loading module from phoslactomycin 
PKS combining with the introduction of the CHC-CoA 
biosynthetic gene cassette into the wild-type strain S. 
avermitilis led to efficiently produce doramectin without 
knocking out the bkd gene and CHC supplementation 
[13]. Recently, the biosynthetic gene cluster of milbemy-
cin was characterized by the whole-genome sequencing 
of S. bingchenggensis [14]. The subsequent inactivation of 
the gene encoding a C5-ketoreductase led to the accumu-
lation of 5-oxomilbemycins A3/A4, which can be used as 
the substrate for the semi-synthesis of milbemycin oxime 
through one step chemical reaction [7]. The milbemycin 
biosynthetic gene cluster mil in S. bingchenggensis con-
sists of four large ORFs (milA1–milA4) encoding giant 
multifunctional polypeptides of PKS, some regulatory 
genes and genes encoding tailoring enzymes (Additional 
file 1: Figure S1), which are highly homologous to aver-
mectin biosynthetic gene cluster ave [15]. Both milbemy-
cin and avermectin PKSs consist of 12 modules, each of 
which contains distinctive active site domains catalyzing 
a specific round of polyketide chain elongation. However, 
the differences between the module and its counterpart, 
such as the module 2, the module 7 and the loading mod-
ule, lead to the structural diversity of avermectin and 
milbemycin (Additional file 1: Figure S1). Base on the fact 
that avermectin and milbemycin are similar molecules, it 
appeared feasible to generate hybrid compounds sharing 
the structural features of avermectin and milbemycin by 
combinatorial biosynthesis.
In order to widen the insecticidal spectra of avermec-
tins and milbemycins, it is desirable to generate new 
derivatives. Herein, ivermectin B1a was produced by the 
replacement of aveDH2-KR2 in the avermectin producer 
S. avermilitis MA-108 with milDH2-ER2-KR2 from S. 
bingchenggensis. The subsequent substitution of aveLAT-
ACP encoding the loading module of avermectin PKS 
with milLAT-ACP from S. bingchenggensis led to two 
hybrid compounds 25-methyl and 25-ethyl ivermectin 
(Fig. 1) simultaneously sharing the structural features of 
avermectins and milbemycins and showing significantly 
enhanced insecticidal activity.
Results
Construction of aveDH2‑KR2 replacement mutant to yield 
ivermectin
On the basis of understanding the biosynthetic path-
ways of avermectin and milbemycin, we attempted to 
construct an ivermectin-producing strain by replacing 
the aveDH2-KR2 of avermectin biosynthetic gene clus-
ter in S. avermitilis NA-108 with milDH2-ER2-KR2 of 
milbemycin biosynthetic gene cluster from S. bingcheng-
gensis (Fig. 2). PCR verification using the primers E1 and 
E2 (Additional file  2: Table S1) demonstrated that the 
expected 2.6-kb DNA fragment encoding MilDH2-ER2-
KR2 was obtained from the genomic DNA of S. 
bingchenggensis and the double-crossover mutant S. aver-
mitilis AVE-T27, whereas no PCR product was detected 
from the genomic DNA of S. avermitilis NA-108 (Fig. 3a, 
b). The PCR product was then sequenced, and the results 
further confirmed that aveDH2-KR2 in avermectin bio-
synthetic gene cluster was successfully replaced with 
milDH2-ER2-KR2 by double crossover. Compared to the 
parental strain S. avermitilis NA-108, strain AVE-T27 
demonstrated a different metabolic profile. As shown in 
Fig. 4, in addition to the disappearance of avermectin “a” 
components and the remarkable decrease of avermectin 
“b” components, a new compound, which showed iden-
tical retention time and molecular mass (m/z  =  897, 
[M+Na]+) to those of the authentic sample ivermectin 
B1a, was detected in culture extracts of S. avermitilis 
AVE-T27 by HPLC analysis. Therefore, the compound 
was considered to be ivermectin B1a, which was consist-
ent with the designed biosynthetic strategy (Fig. 2).
Second domain swap to yield new hybrid antibiotics
In order to obtain more avermectin analogs and fur-
ther investigate the structure–activity relationship of 
milbemycins and avermectins, the loading module of 
avermectin PKS encoding by aveLAT-ACP in the iver-
mectin-producing strain S. avermitilis AVE-T27 was 
replaced by that of milbemycin PKS encoding by mil-
LAT-ACP in milbemycin-producing strain S. bingcheng-
gensis (Fig.  2). After the successive treatment of the 
transformants growing at a non-permissive temperature 
(39  °C) and under non-selective antibiotic pressure, 100 
apramycin-sensitive strains were randomly selected and 
examined by fermentation experiments and HPLC analy-
sis. Compared to strain AVE-T27, 91 apramycin-sensitive 
strains demonstrated distinct metabolic profiles, in which 
ivermectin B1a, avermectins B1a and B2a disappeared 
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but two new compounds 1 and 2 with a molecular ion 
at m/z = 869.53 [M+Na]+ and 855.30 [M+Na]+, respec-
tively, were detected (Additional file  3: Figure S2). The 
double crossover event occurred in strain AVE-H39 with 
the highest yield of the new compounds was then veri-
fied by PCR analysis using a pair of primers V1/V2 (Addi-
tional file 2: Table S1), which was designed to amplify the 
internal fragment of milLAT-ACP. As shown in Fig.  3d, 
the expected 1.32-kb DNA fragment was obtained from 
the genomic DNA of S. bingchenggensis and the mutant 
strain AVE-H39, whereas no PCR product was detected 
from the genomic DNA of AVE-T27. The result implied 
that the aveLAT-ACP in strain AVE-T27 was successfully 
replaced with milLAT-ACP by double crossover, which 
was further confirmed by sequencing the PCR product.
The structure elucidation of hybrid compounds 1 and 2
Compound 1 (Fig. 1) was isolated as a white amorphous 
powder. Its molecular formula was determined to be 
C46H70O14 on the basis of HRESIMS at m/z 869.4652 
[M+Na]+ (calcd 869.4663 for C46H70O14Na) and 13C 
NMR data (Additional file  4: Table S2). The 1H NMR 
spectrum of compound 1 (Additional file  5: Figure S3) 
displayed four doublet aliphatic methyls at δ 0.82 (d, 
J = 6.3 Hz), 1.15 (d, J = 6.9 Hz), 1.25 (d, J = 6.1 Hz), 1.27 
(d, J =  6.4 Hz); two olefinic methyl signals at δ 1.50 (s), 
1.87 (s); two methoxy signals at δ 3.42 (s), 3.43 (s); one 
trans-double bond at 5.72 (overlap), 5.73 (overlap). Its 
13C NMR (Additional file  6: Figure S4) revealed 46 car-
bon resonances, including an ester carbonyl carbon at δ 
174.07, a ketal carbon at 97.63, five sp2 methines, three 
sp2 quaternary carbons, four secondary methyls, two 
vinylic methyls, one primary methyl, nine methylenes, 
seventeen aliphatic methines (fourteen oxygenated), one 
oxygenated quaternary carbon, and two methoxy groups. 
Comparison of the 1H and 13C NMR spectral data of 1 
with those of avermectin B1b revealed that compound 
1 was structurally related to avermectin B1b except for 
the differences at C22–C23 and C25, where the isopropyl 
group at C25 and the unsaturated bond between C22 and 
C23 in avermectin B1b were replaced by an ethyl group 
and a saturated bond in compound 1, respectively [16]. 
Fig. 2 Predicted products of engineered avermectin PKS. a AVE A1 of avermectin PKS. b AveDH2‑KR2 in module 2 of avermectin PKS was replaced 
with MilDH2‑ER2‑KR2 of milbemycin PKS. c AveDH2‑KR2 in module 2 and loading module AveLAT‑ACP of avermectin PKS were replaced with 
MilDH2‑ER2‑KR2 of and loading module MilLAT‑ACP of milbemycin PKS, respectively
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The correlations of H-25, H-26 and H-27 in the 1H-1H 
COSY spectrum and the HMBC correlations from H-26 
to C-25 and C-27 confirmed the presence of an ethyl 
group at C-25 in compound 1 (Additional file  7: Figure 
S5). The HMBC correlation between H-22, C-21, C-23 
and C-24 indicated the saturated bond between C-22 
and C-23. As a consequence, the gross structure of 1 was 
established as 25-ethyl ivermectin (Fig.  1). Compound 
2 was also obtained as a white amorphous powder. Its 
molecular formula was determined to be C45H68O14 on 
the basis of HRESIMS at m/z 855.4508 [M+Na]+ (calcd 
855.4507 for C45H68O14Na). Comparison of the 1H and 
13C NMR data (Additional file  4: Table S2) with those 
of 1 indicated that compound 2 and 1 differed only at 
C25, in that the ethyl group at C-25 in compound 1 was 
replaced by a methyl group in 2, which was supported by 
1H-1H COSY correlations of H-25 and H-26 and HMBC 
correlations from H26 to C24 and C25 (Additional file 7: 
Figure S5). As a result, the structure of 2 was established 
as 25-methyl ivermectin (Fig. 1). The 1D- and 2D-NMR 
spectra of compounds 1 and 2 can be found in the sup-
plemental material (Additional files 5, 6, 7, 8, 9, 10, 11, 12, 
13, 14, 15: Figures S3–S13).
The bioactivity of hybrid compounds 1 and 2
The insecticidal activity of compounds 1 and 2 against 
C. elegans and M. separate was evaluated and compared 
to that of commercial insecticides milbemycin and iver-
mectin. The results demonstrated that the lethal effects 
of the tested compounds were enhanced with increased 
concentrations, indicating that the insecticidal activ-
ity was dose-dependent. However, the mixture of 1 and 
2 possessed higher insecticidal activities against C. ele-
gans and M. separate than milbemycin and ivermectin. 
Fig. 3 Gene replacement in S. avermitilis NA‑108. a Schematic description of the gene replacement of aveDH2‑KR2 in S. avermitilis NA‑108 with 
milDH2‑ER2‑KR2 from S. bingchenggensis via double crossover. b PCR analysis with genomic DNA from S. avermitilis NA‑108, S. avermitlis AVE‑T27 and 
S. bingchenggensis, using primers E1 and E2. Lane 1 S. bingchenggensis; Lane 2 S. avermitilis AVE‑T27; Lane 3 S. avermitilis NA‑108; Lane 4 DNA ladder. c 
Schematic description of the gene replacement of aveLAT‑ACP in S. avermitilis AVE‑T27 with milLAT‑ACP from S. bingchenggensis via double crosso‑
ver. d PCR analysis with genomic DNA from S. avermitilis AVE‑T27, S. avermitlis AVE‑H39 and S. bingchenggensis, using primers V1 and V2. Lane 1 DNA 
ladder; Lane 2 S. bingchenggensis; Lane 3 S. avermitilis AVE‑T27; Lane 4 S. avermitilis AVE‑H39
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As listed in Table 1, the LC50 of the mixture of 1 and 2 is 
2.2 ± 0.7 μg/ml, which is approximately 2.5-fold and 4.6-
fold lower than that of milbemycin (5.42  ±  2.1  μg/ml) 
and ivermectin (10.1 ± 1.3 μg/ml), respectively. Moreo-
ver, it exhibited impressive insecticidal activity against M. 
separata with a LC50 of 19.4 ± 1.3 μg/ml, which is 5.7-
fold lower than that of milbemycin (110.7 ± 7.4 μg/ml).
Genetic stability of AVE‑T27 and AVE‑H39
The genetic stabilities of strains AVE-T27 and AVE-H39 
to produce ivermectin B1a and compounds 1 and 2 were 
evaluated by five successive subcultivation tests. The 
shaking flask experiments and HPLC analysis showed 
that the yield of ivermectin B1a and 25-methyl/25-ethyl 
ivermectin produced by AVE-T27 and AVE-H39 among 
five generations ranged from 3450 ± 65 to 3510 ± 37 μg/
ml and 3045 ± 78 to 3087 ± 46 μg/ml, respectively. These 
results suggested that strains AVE-T27 and AVE-H39 
were genetically stable and could be applied in industry.
Discussion
Since the discovery of avermectin in 1975, many efforts 
have been devoted to its structural modification to yield 
avermectin derivatives. To date, six avermectins (abamec-
tin, ivermectin, doramectin, emamectin, eprinomectin 
and selamectin) have been commercialized and widely 
used as anthelmintic and insecticidal drugs in animal 
health and agriculture [17]. The structural differences of 
these drugs are located on C25, C22–C23 and C13 posi-
tions. For example, ivermectin (22,23-dihydroavermectin 
B1), which is synthesized by chemical reduction of the 
double bond between C22 and C23 of avermectins B1, 
exhibits the same effective antiparasitic activity but lesser 
toxic side effect than avermectins B1 [18]. Doramectin 
(C25-cyclohexyl avermectin B1), an avermectin analog 
with a cyclohexyl group at C25, demonstrates better 
pharmacokinetic properties and efficacy than avermectin 
[19]. Compared to avermectin, eprinomectin, emamec-
tin and selamectin possess different groups at C13 and 
show unique pharmacokinetic characteristics. The vari-
ous applications of avermectins in agricultural and vet-
erinary fields have attracted much attention, and more 
avermectin analogs with high insecticidal and acaricidal 
activity have been reported [20, 21]. Milbemycins are a 
group of 16-membered macrolides chemically related to 
avermectins with the major structural differences at C25, 
C22–C23 and C13. Due to the high and broad-spectrum 
activity against insects and parasites, low toxicity to 
mammals, and environment friendliness, milbemycins 
have received considerable interest in agricultural chem-
istry, and four kinds of milbemycins including milbe-
mectin (a mixture of milbemycins A3/A4), milbemycin 
oxime, lepimectin, and latidectin have been marketed 
and used as a broad-spectrum acaricide, anthelmintic 
and insecticide [7, 22]. Although the natural avermectins 
Fig. 4 HPLC analysis of the mycelial extracts from the parental and 
mutant strains. a S. avermitilis NA‑108; b S. avermitlis AVE‑T27; c stand‑
ard sample ivermectin B1a; d S. avermitilis AVE‑H39. B1a avermectin 
B1a, B2a avermectin B2a, B1b avermectin B1b, B2b avermectin B2b, Ive 
B1a ivermectin B1a, 1 compound 1, 2 compound 2
Table 1 Insecticidal activity of the mixture of 1 and 2 com-
pared with those of milbemycins A3/A4 and ivermectin
a The mixture contains 70 % compound 1 and 30 % compound 2
b Milbemycins A3/A4 contains 70 % A4 and 30 % A3
c Values are the means ± SDs of three independent experiments
Samples LC50 (μg/ml)
c
C. elegans M. separata
The mixture of 1 and 2a 2.2 ± 0.7 19.4 ± 1.3
Milbemycin A3/A4b 5.4 ± 2.1 110.7 ± 7.4
Ivermectin 10.1 ± 1.3
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and milbemycins demonstrate structural differences, 
some commercial avermectins and milbemycins share 
the same structural features. For example, selamectin and 
ivermectin contain a saturated bond at C22–C23, which 
is similar to milbemycins; while latidectin and lepimec-
tin contain 13-substituted groups, the modified pattern 
of which is different from milbemectin and milbemycin 
oxime, but similar to avermectins. Inspired by the struc-
ture–activity relationship of avermectins and milbe-
mycins, series of compounds with the partial structural 
features of milbemycins and avermectins were synthe-
sized and showed potential insecticidal activity [23].
The polyketide backbond of avermectin and milbe-
mycin is biosynthesized by the multifunctional and 
multimodular proteins referred as type I polyketide syn-
thetases (type I PKSs). The type I PKSs consist of sev-
eral modules, each of which always carries three core 
domains acyltransferase (AT), acyl carrier protein (ACP) 
and ketosynthase (KS) as well as other accessory domains 
KR, DH and ER [24]. The organization of the modular 
PKSs allows a wide range of complex polyketide prod-
ucts to be assembled from simple precursors. Given the 
increased understanding of biosynthetic machineries of 
polyketides, combinatorial biosynthesis by rearranging 
the domains in PKSs has been developed as an alterna-
tive strategy to generate novel unnatural polyketides [25, 
26]. Although milbemycin biosynthetic gene cluster mil 
and avermectin biosynthetic gene cluster ave demon-
strate different gene organizations, both of them contain 
four large ORFs (milA1–milA4/aveA1–aveA4), a regula-
tory gene (milR/aveR) and some genes encoding tailoring 
enzymes (milC/aveC, milE/aveE, milF/aveF, milD/aveD) 
(Additional file 1: Figure S1). The four large ORFs encode 
the PKS, which is responsible for the biosynthesis of pol-
yketide backbond and consists of a loading module and 
12 elongating modules. These homologous ORFs in mil 
and ave share high identity in protein sequences rang-
ing from 48.41 to 64.78  %, leading to a similar polyke-
tide backbone observed in milbemycin and avermectin. 
However, the differences at the loading module, module 
2 and module 7 are believed to be associated with the 
structural changes at C25, C22–C23 and C13 positions. 
Inspired by the structural diversity and impressive bio-
activity of milbemycins and avermectins, two new aver-
mectin derivatives were designed by reconstructing the 
biosynthetic pathway of avermectins (Fig. 2). Firstly, the 
aveDH2-KR2 of avermectin biosynthetic gene cluster 
in S. avermitilis NA-108 was replaced by milDH2-ER2-
KR2 of milbemycins biosynthetic gene cluster from S. 
bingchenggensis to yield the ivermectin-producing strain 
AVE-T27. Compared to the parental strain NA-108, 
strain AVE-T27 no longer produced “b” components of 
avermectins (Fig.  4b), and the yield of avermectin B1a 
and B2a (259  ±  23 and 173  ±  18  μg/ml, respectively)
decreased approximately 7 fold and 2.3 fold, respectively. 
The remarkable decrease in the yield of avermectins was 
also observed in other ivermectin-producing strains [6, 8, 
11]. It is obvious that strain NA-108 only produces four 
components of avermectins, of which the “a” components 
B1a and B2a are produced in quantity (Fig. 4a), suggest-
ing that the loading module of the avermectin PKS in 
strain NA-108 may dominantly utilize 2-methylbutyryl 
as the starter unit for polyketide assembly. Therefore, 
the substitution of aveDH2-KR2 by milDH2-ER2-KR2 
resulted in the substantial accumulation of ivermectin 
B1a, whereas the yield of ivermectin B1b may be too low 
to be detected (Fig. 4b). Before the thorough understand-
ing the function of AveC in avermectin biosynthesis [27], 
the unsaturated bond of C22–C23 was considered to be 
formed through the optional dehydration by partially 
active dehydratase (DH) in module 2 with the assistance 
of AveC [28]. Therefore, several attempts have been made 
to construct ivermectin-producing strains by replacing 
the partially active DH with completely active DH and 
ER from other PKSs through the genetic manipulation 
of avermectin biosynthetic gene cluster. However, the 
yield of ivermectin produced by the genetic engineered 
strains is too low for large-scale production probably due 
to the poor folding of the hybrid PKSs and unfavorable 
protein–protein interactions [6, 8, 11]. Thus, ivermectin 
is still synthesized by a regiospecific hydrogenation at 
C22–C23 of avermectins using rhodium chloride as the 
catalyst, even though this process suffers from expensive 
cost and heavy metal pollution [6]. It is worth noting that 
strain AVE-T27 demonstrated excellent performance in 
producing ivermectin B1a with a yield of 3450 ± 65 μg/
ml, which is only slightly lower than the total amount of 
avermectins (3577 ± 26 μg/ml) produced by the parental 
strain NA-108. It is commonly reported that PKS bioen-
gineering experiments often produce new compounds at 
compromised yields [6, 8, 10, 11, 24, 29]. For examples, 
the total amount of avermectins and ivermectins pro-
duced in the ivermectin-producing strains Ive12-4 and 
OI-31, which were constructed by replacing the AveDH2-
KR2 in S. avermitilis Olm73-12 with PikDH4-ER4-KR4 
from pikromycin PKS and OlmDH3-ER3-KR3 from 
oligomycin PKS, respectively, was estimated to be only 
1–3  % of the amount of avermectins produced by the 
parental strain or decreased approximately eightfold 
[6, 8]. Compared to PikDH4-ER4-KR4 (46.48  %) and 
OlmDH3-ER3-KR3 (43.06  %), MilDH2-ER2-KR2 dem-
onstrates a higher identity (51.50 %) with AveDH2-KR2. 
Furthermore, both of MilDH2-ER2-KR2 and AveDH2-
KR2 catalyze the reduction of C22–C23 in the similar 
polyketide backbone. Therefore, it is no surprise that the 
substitution of AveDH2-KR2 with MilDH2-ER2-KR2 
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could not lead to the drastic decrease in the total amount 
of avermectins and ivermectin. Indeed, the use of alter-
native domains and modules from PKSs of structurally 
related polyketides is considered as an efficient approach 
to generate hybrid PKSs with high yield [30]. The high 
yield of ivermectin B1a produced by strain AVE-T27 
implied that the DH2-ER2-KR2 from milbemycin PKS 
may be more suitable for swapping AveDH2-KR2 than 
the domains from other PKS reported previously [6, 8, 
11]. We speculated that the domain swapping between 
AveDH2-KR2 and MilDH2-ER2-KR2 does not seri-
ously affect the substrate specificity of the KS domain 
and dynamic KS:ACP interaction, which are believed to 
play crucial roles in polyketide chain transfer and elon-
gation [10, 24]. However, strain AVE-T27 still produced 
a small amount of avermectins B1a and B2a, suggest-
ing the incompletable function of MilDH2-ER2-KR2 
in hybrid PKS. Recently, Sun et  al. have revealed a dual 
function of AveC, which works as a spirocyclase and an 
independent dehydratase, involved in the spiroketal for-
mation and the optional dehydration of C22–C23 during 
the avermectin biosynthesis [27]. Due to the complete 
inactivity of AveDH2, AveC was believed to be the only 
factor responsible for C22-C23 dehydration to yield the 
“1” components of avermectins. This dehydration reac-
tion is post-PKS but precedes spiroketal formation, and 
the spirocyclase activity of AveC can tolerate variation 
of the C22-C23 bond. Therefore, we assumed that parts 
of avermectin B1a produced by AVE-T27 are formed by 
the incompletable activity of MilDH2-ER2-KR2 during 
skeleton assembly process, while the others are probably 
associated with the optional dehydratase activity of AveC 
in the post-PKS modification.
Loading modules of type I PKSs catalyze selec-
tion and recruitment of starter units into polyketides. 
Accordingly, starter units are incorporated into pol-
yketides at only one position, and swapping of the 
loading module can lead to changes in the side chain 
originating from the starter unit [24, 31]. For example, 
the replacement of the loading module of the eryth-
romycin PKS or spinosyn PKS by that of avermectin 
PKS resulted in the production of novel erythromy-
cin or spinosyn analogs [32, 33]. Recently, it has been 
reported that the replacement of the loading module 
of avermectin PKS with that of phoslactomycin PKS, 
which prefers cyclohexylcarbonyl-CoA as the start 
unit, led to enhanced ratio of doramectin to avermec-
tins produced by genetic engineered S. avermitilis 
[13]. Therefore, the loading module of avermectin PKS 
could be a suitable site for module swapping to gener-
ate unnatural avermectins. After the replacement of 
the loading module of avermectin PKS in strain AVE-
T27 by that of milbemycin PKS, two new avermectin 
derivatives with a methyl or ethyl group at C25 posi-
tion were obtained (Fig. 1). The loading module of aver-
mectin PKS possesses broad substrate specificity, for 
example, it can use 2-methylbutyryl-CoA, isobutyryl-
CoA and cyclohexylcarbonyl-CoA as substrates to bio-
synthesize avermectin “a” components, avermectin “b” 
components and doramectin, respectively [2, 34]. How-
ever, the loading module of milbemycin in S. bingcheng-
gensis seems to only use acetyl-CoA and propionyl-CoA 
as substrates to biosynthesize 25-methyl and 25-ethyl 
milbemycins, respectively [15]. Therefore, it was spec-
ulated that the loading module of avermectin PKS 
possesses a broader substrate specificity than that of 
milbemycin PKS. Compared to the yield of ivermectin 
produced by AVE-T27, the total amount of 25-methyl 
and 25-ethyl ivermectin (3045  ±  78  μg/ml) produced 
by AVE-H39 is satisfory. However, no avermectins with 
C25-isopropyl, C25-isobutyl groups were detected 
(Fig.  4d), which confirmed the relatively narrow sub-
strate specificity of the loading module of milbemycin 
PKS. Although the loading module of avermectin PKS 
exhibits an identity of 46.54 % with that of milbemycin 
PKS on protein level, it seems that the domain swap-
ping between them did not seroiusly affect the biosyn-
thetic ability of the resultant hybrid PKS. The high yield 
of 25-methyl and 25-ethyl ivermectin again confirmed 
that the use of alternative modules from PKSs of struc-
turally related polyketides is an efficient approach to 
generate hybrid polyketides.
The previous structure–activity relationship studies 
of avermectins suggested that C5, C13 and C22–C23 
are essential for the bioactivity, and the subsequent 
modification at these positions successfully developed 
several commercial drugs such as ivermectin, emamec-
tin, eprinomectin and selamectin [17]. Although some 
C25-substitituted avermectins were designed [34–36], 
only doramectin with a cyclohexyl group at C25 was 
commercialized. Compared to ivermectin, compounds 1 
and 2 exhibited significantly enhanced insecticidal activ-
ity, implying that the C25 is a potential target for struc-
tural modification, which provides new clues for the 
structural modification of avermectins.
Conclusions
In conclusion, 25-methyl and 25-ethyl ivermectin were 
obtained by domain swapping. The impressive insecti-
cidal activity of these two new compounds suggested 
their promising use as novel insecticides in agriculture. 
Furthermore, the high yield and genetic stability of the 
engineered strains S. avermitilis AVE-T27 and AVE-
H39 highlight their potential in industrial production 
of ivermectin B1a and 25-methyl/25-ethyl ivermectin, 
respectively.
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Materials and methods
Strains, vectors, reagents, and cultivation
All bacterial strains and plasmids used in this study 
are listed in Table  2. The initial strain S. avermitilis 
NA-108, originating from the mutation of S. avermitilis 
NEAU1069, can only produces “B” components of aver-
mectins with high yield but does not produce “A” com-
ponents of avermectins and oligomycin. S. avermitilis 
NEAU1069 and S. bingchenggensis have been deposited 
at the China General Microbiology Culture Collection 
Center, Institute of Microbiology, Chinese Academy of 
Science with accession numbers of CGMCC2943 and 
CGMCC1734, respectively. The 16S rDNA sequence of S. 
avermitilis NEAU1069 and S. bingchenggensis was depos-
ited in GenBank with accession numbers of DQ768097 
and DQ449953, respectively. Primers (Additional file  2: 
Table S1) were synthesized in Sangon Biotech (Shanghai, 
China). Restriction endonucleases, DNA ligase, and DNA 
polymerases were purchased from TaKaRa Biotechnol-
ogy (Dalian, China). DNA sequencing was performed by 
GenScript (Nanjing, China). MS (mannitol soya flour) 
medium was used for S. avermilitis NA-108 sporulation 
and conjugation between Escherichia coli and Strepto-
myces. YEME (yeast extract-malt extract) medium con-
taining 25  % sucrose was used to grow mycelia for the 
isolation of total DNA [37]. Luria–Bertani (LB) medium 
was used for E. coli propagation [38]. All E. coli proce-
dures were performed according to standard proto-
cols [38]. Isolation of genomic DNA from S. avermitilis 
NA-108 and agarose gel electrophoresis were performed 
according to the standard methods [37, 38].
Construction of aveDH2‑KR2 replacement mutant strain
In order to replace the DNA region encoding DH2-
KR2 of avermectin PKS (aveDH2-KR2) with the DNA 
fragment encoding DH2-ER2-KR2 of milbemycin PKS 
(milDH2-ER2-KR2), recombinant plasmid pER-4 was 
constructed. Using genomic DNAs of S. avermitilis 
NA-108 as template, a 1106-bp fragment upstream of 
the aveDH2-KR2 was amplified with primers a1 and 
a2. The amplified fragment was digested with HindIII/
XbaI and ligated into corresponding sites of pUC19 to 
generate pER-1. Then, a 1055-bp fragment downstream 
of the aveDH2-KR2 amplified with primers c1 and c2 
was digested with XbaI/EcoRI and then ligated to the 
corresponding sites of pER-1 to yield pER-2. The intro-
duction of XbaI site did not change the natural amino 
acids sequence at the linker regions. The milDH2-ER2-
KR2 (3120-bp) fragment was amplified with primers b1 
and b2 using genomic DNAs of S. bingchenggensis as 
Table 2 Strains and plasmids used in this study
a AmpR ampicillin resistance, AmR apramycin resistance
Strains/plasmids Relevant characteristicsa References
Strains
 E. coli
  DH5α Host strain for cloning Invitrogen
  ET12567/
pUZ8002
Donor strain for conjugation Kieser et al. [37]
 S. bingchenggensis The milbemycin‑producing strain Wang et al. [14]
 S. avermitilis
  NA‑108 Mutant strain of S. avermitilis NEAU1069 producing “B” components  
of avermectins as main secondary metabolites
This study
  AVE‑T27 Mutant strain of NA‑108 with the replacement of aveDH2‑KR2 by milDH2‑ER2‑KR2 This study
  AVE‑H39 Mutant strain of AVE‑T27 with the replacement of aveLAT‑ACP by milLAT‑ACP This study
Plasmids
  pUC19 Cloning vector for E. coli, AmpR TaKaRa
  pKC1139 E. coli‑Streptomyces shuttle vector, AmR Kieser et al. [37]
  pER‑1 pUC19 derivative containing aveDH2‑KR2 upstream fragment, AmpR This study
  pER‑2 pUC19 derivative containing aveDH2‑KR2 upstream and downstream fragments, AmpR This study
  pER‑3 pUC19 derivative containing milDH2‑ER2‑KR2 together with aveDH2‑KR2  
upstream and downstream fragments, AmpR
This study
  pER‑4 pKC1139 derivative containing milDH2‑ER2‑KR2 together with aveDH2‑KR2  
upstream and downstream fragments, AmR
This study
  pLM‑1 pMD19‑T derivative containing milLAT‑ACP together with aveLAT‑ACP  
upstream and downstream fragments, AmpR
This study
  pLM‑2 pKC1139 derivative containing milLAT‑ACP together with aveLAT‑ACP  
upstream and downstream fragments, AmpR
This study
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template, and the resultant PCR products were cloned 
into the XbaI sites of pER-2 to give pER-3. The 5.27-kb 
insert was recovered from pER-3 by digesting with Hin-
dIII/EcoRI and inserted into the same sites of pKC1139 
to generate pER-4. After the verification by PCR ampli-
fication and restriction digestion analysis, pER-4 was 
transformed into the non-methylating E. coli ET12567/
pUZ8002. The conjugations were performed using the 
spores of S. avermitilis NA-108 according to the litera-
ture [16] and exconjugants were selected using MS agar 
containing apramycin. These cultures were grown at 
28 °C for 2 days, then at 39 °C for 7–10 days. The colonies 
that were apramycin-resistant at 39  °C were identified 
as the integrating mutants, in which a single-crossover 
homologous recombination event took place. Insertion 
mutants were confirmed by PCR analysis and inoculated 
on nonselective MS plates at 28 °C for a second round of 
recombination. Double crossover mutants were screened 
by replica from the colonies grown on the MS medium. 
Mutants that lost resistance to apramycin were selected 
for further screening and genotypic confirmation by PCR 
using E1 and E2 as primers. The obtained double-crosso-
ver mutant was designated as AVE-T27.
Construction of aveLAT‑ACP replacement mutant strain
To construct plasmid pLM-2 for replacement of the 
gene encoding the loading module of avermectin PKS 
(aveLAT-ACP) with that of milbemycin PKS (milLAT-
ACP), the overlap extension PCR was employed [39]. 
Firstly, three pairs of primers A1/A2, B1/B2 and C1/
C2 were designed to amplified 5′flank of aveLAT-ACP 
(1008-bp), milLAT-ACP (1407-bp) and 3′flank of ave-
LAT-ACP (1022-bp), respectively. Then a two-step PCR 
was employed: in the first round PCR, three fragments 
were mixed in a ratio of 1:3:1 (total DNA amounts about 
250  ng), with 0.2  mM of each dNTP, 0.5 U PrimeSTAR 
HS DNA polymerase (Takara, Dalian, China), 1× Prime-
STAR Buffer (Mg2+ plus), and 10 % DMSO, the PCR pro-
gram consisted of 12 repetitive cycles with a denaturation 
step at 94 °C for 30 s, an annealing step at 57 °C for 15 s 
and an elongation step at 72 °C for 3 min; in the second 
round PCR, 4 μl reactants from above was took as tem-
plate, primers A1/C2 and other reagents were added, 
the PCR program consisted of 25 repetitive cycles with 
a denaturation step at 94 °C for 30 s, an annealing step at 
60.6 °C for 15 s and an elongation step at 72 °C for 4 min. 
A 3400-bp fragment was obtained and ligated to pMD19-
T (Takara, Dalian, China) to generate pLM-1. After 
sequencing and PCR analysis, the 3.4-kb fusion fragment 
was recovered from pLM-1 by digesting with HindIII/
XbaI and inserted into the same sites of pKC1139 to gen-
erate pLM-2. Following the procedure described above, 
pLM-2 was introduced into strain AVE-T27 for a second 
replacement. After the validation by PCR amplification 
using V1 and V2 as primers, the obtained double-crosso-
ver mutant was designated as AVE-H39.
Fermentation and HPLC analysis of antibiotic production
S. avermitilis NA-108 and all genetically engineered 
strains were fermented under the same culture condi-
tion. The strains were firstly cultured in seed medium 
(corn starch 2  %, glucose 0.5  %, yeast extract 1  %, 
cottonseed cake 1  %, and CoCl2·6H2O 0.005  %, pH 
7.2) at 28  °C for 42  h on a rotary shaker at 250  rpm. 
Then 2.0  ml of the culture was transferred into 250-
ml Erlenmeyer flasks containing 25  ml of the fer-
mentation medium consisting of corn starch 80  g/l, 
glucose 5  g/l, peptone10  g/l, cottonseed cake 10  g/l, 
NaCl 1  g/l, K2HPO4·3H2O 1  g/l, MgSO4·7H2O 1  g/l, 
CaCO3 1 g/l and CoCl2·6H2O 5 mg/l, pH 7.0. Fermen-
tation was carried out at 28  °C for 8  days on a rotary 
shaker at 250  rpm. After finishing the fermentation, 
the broths were mixed with an equal volume of meth-
anol. The resultant mixture was then centrifuged at 
12,000×g for 20 min, and the supernatant was filtered 
through a 0.22  μm membrane filter and analyzed by 
HPLC. HPLC was performed with a Shimadzu LC-
2010CHT system (Shimadzu, Koyoto, Japan) by using 
a NOVA-PAKR C18 column (3.9  ×  150  mm, 5  μm, 
Waters, Milford, MA) at a flow rate of 1.0  ml/min, 
CH3OH/H2O (85:15, v/v) and detected at 246  nm. 
For LC/MS analysis, the positive electrospray ioni-
zation mass spectra were obtained from a Waters 
Q-TOF Micro LC–MS-MS spectrometer (electro-
spray voltage, 3.5  kV; heated capillary temperature, 
450 °C; gas flow, 900 l/h) coupled with a Agilent HPLC 
1200 system equipped with a Eclipse  ×  DB-C18 col-
umn (4.6  ×  150  mm, 5  μm) using a mobile phase of 
CH3OH/H2O (80:20, v/v). The flow rate was 0.3  ml/
min, and the detection was at 246 nm.
Purification of hybrid antibiotics
The hybrid antibiotics produced by the recombinant 
strain AVE-H39 were purified from the culture broth. 
After the fermentation, the broth (5  l) was centrifu-
gated, and the resulting cake was washed with H2O. 
MeOH (10 l) was used to extract the washed cake. The 
MeOH extract was evaporated under reduced pres-
sure to approximately 0.2  l at 45  °C and the result-
ing concentrate was extracted three times using an 
equal volume of EtOAc. The combined EtOAc phase 
was concentrated under reduced pressure to yield oily 
substances. The residual oily substance was chroma-
tographed on silica gel and eluted with a petroleum 
ether-acetone mixture (95:5–50:50, v/v). The fractions 
eluted with the petroleum ether-acetone mixture 
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(95:5–75:25, v/v) were combined and evaporated to 
obtain a crude mixture. The crude mixture was then 
subjected to semipreparative HPLC (Agilent 1100, 
Zorbax SB-C18, 5  μm, 9.4  ×  250  mm; 1.5  ml/min; 
246  nm) by eluting with CH3OH-H2O (80:20, v/v) to 
afford compound 1 and 2.
Structural analysis and bioactivity of hybrid antibiotics
The HRESI-MS spectra were taken on a Q-TOF Micro 
LC–MS-MS spectrometer (Waters, Milford, MA, 
USA) and an API QSTAR time-of-flight spectrom-
eter, respectively. 1D- and 2D-NMR spectra were 
recorded on Bruker AM-400 and DRX-600 spectrom-
eters (Bruker, Rheinstetten, Germany) using 2.5  mm 
microcells (Synthware) for CDCl3. The 7.26 ppm and 
77.23  ppm resonance of CDCl3 was used as internal 
references for 1H NMR spectra and 13C NMR spectra, 
respectively. The insecticidal activity of the mixture of 
compounds 1 and 2 against the second-instar larva of 
M. separata was measured by the leaf-dipping method 
[17]. Briefly, the test sample was dissolved in metha-
nol at a concentration of 100  μg/ml and diluted to 
appropriate concentrations with distilled water con-
taining 1  % Tween 80. Wafer discs (1-cm diamemter, 
1-mm-thick) made from fresh wild corn leaves were 
dipped into the diluted solutions of the test sample 
for 3 s, and then taken out and kept in a conditioned 
room. The number of dead larvae was recorded at 
48 h after treatment, and the corrected mortality was 
calculated. The insecticidal activity of the test sample 
against C. elegans was evaluated according to methods 
described previously [40]. The appropriate amounts 
of the diluted solutions of the test sample were added 
to 1-l portion of an aqueous suspension containing 
living nematodes C. elegans. The mixtures were kept 
at 25 °C for 15 h after shaking. The number of nema-
todes that were immobilized and the total number of 
nematodes tested were counted under a stereoscopic 
microscope. Immobilized rates against the total num-
ber of tested nematodes were calculated. The insec-
ticidal activity was expressed as LC50 values, which 
were calculated by the LOGIT method. Milbemycin 
A3/A4 (A3:A4  =  3:7) and ivermectin were used as 
positive controls.
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